CA
NZ
UK
AU
IND
US
The Hain Celestial Group (NASDAQ:HAIN) was up 9.62% to USD 0.1470 in pre-market trading on November 3, 2026, against the Monday, November 2 close. The screen price is used as given.
Grab Holdings (NASDAQ:GRAB) was up 9.79% to USD 3.14 in pre-market trading on November 3, 2026, against the Monday, November 2 close. The move follows the company's third quarter 2026 results, which it said showed all three core segments profitable in the same quarter …
The likely driver is a regulatory filing dated November 2, 2026 that described a preferred share conversion inducement agreement. The filing points to a sizeable increase in the number of shares that could reach the market.
No company announcement dated between October 30 and November 3, 2026 was identified. The decline appears to be a continuation of volatile trading in a thinly capitalized stock rather than a response to a disclosed event.
Fabrinet (NYSE:FN) was up 9.95% to USD 346.00 in pre-market trading on November 3, 2026, against the Monday, November 2 close. The catalyst is clear: the company reported first quarter fiscal 2027 results after the market closed on November 2, and the numbers came …
flyExclusive, Inc. (NYSEAMERICAN:FLYX) was down 9.70% to USD 0.93 in pre-market trading on November 3, 2026, measured against the November 2, 2026 close. The stock is now below USD 1, which puts it firmly inPenny Stockterritory.
Eshallgo (NASDAQ:EHGO) was up 21.97% to USD 2.33 in pre-market trading on November 3, 2026. The move is measured against the Monday, November 2, 2026 close.
According to a company press release dated November 2, 2026, total revenue for the quarter ended September 30, 2026 was USD 110.0 million, compared with USD 231.1 million a year earlier. The company reported a net loss of USD 32.7 million againstNet Incomeof USD …
Market data showed a 52-week range of USD 2.34 to USD 109.60 as of the October 23, 2026 close, a span that reflects reverse-split adjustments as well as heavy selling.
On November 2, 2026, market reports said Usona Institute had submitted aMarketingapplication to the FDA for psilocybin in major depressive disorder. Reports tied Monday's decline in psychedelic developers to concern about competition in the race for a first approval. The company itself did not …
Please wait processing your request...